A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

RubiconMD Secures $18M in Series C Financing Led by Deerfield Management Company

RubiconMD, the leading eConsult platform providing access to specialist expertise, today announced it raised $18 million in Series C funding led by Deerfield Management Company.

Also participating in this investment round are existing investors including Optum Ventures, HLM Venture Partners, Waterline Ventures and Heritage Provider Network. To date, the Company has raised more than $40 million.

As part of the financing round, RubiconMD is adding Julian Harris, M.D., Partner at Deerfield, to the Company’s Board of Directors. Trained as a primary care physician, Dr. Harris has played a key role in helping to accelerate the country’s shift towards value-based payment through senior roles in the public and private sector.

“We are at a crucial moment in the shift towards a value-based health care system, with private and public payers seeking to find innovative ways to improve quality and affordability,” Dr. Harris said. “By enabling primary care clinicians to practice at the top of their license, RubiconMD serves as a vital partner for the country’s most innovative primary care groups, helping them to improve outcomes for patients and to reduce costs for our system.”

Optum Ventures, who co-led the Company’s last round of funding, joined Deerfield in the current round. “By removing the barriers to receiving specialty insights in all settings of care, RubiconMD is driving healthcare towards a more accessible, value-based ecosystem,” said Laura Veroneau, Partner at Optum Ventures and Board member. “RubiconMD has seen remarkable growth and we are thrilled to continue partnering in their work to bring the healthcare industry into the future.”

Motivated by their own experiences within the healthcare system, CEO Gil Addo and President Carlos Reines founded RubiconMD in 2013 to bridge the gap between primary and specialty care. Today, the platform offers quick access to specialist insights across more than 120 specialties. The company has partnered with the top payors in the country to scale its offering.

“We are delighted to bring on Deerfield as an investor,” said Addo. “Deerfield’s experience, reach and commitment to realizing the future of healthcare will be pivotal as we continue to break down barriers to access and ensure all patient populations receive the care they need.”

The Company expects to use the new capital to fuel its ongoing growth. RubiconMD also plans to leverage its data to deliver new product offerings to better serve primary care clinicians. “Our goal has always been to empower primary care.” said Reines. “We remain focused on ensuring that the right information is delivered into the hands of the primary care clinician at the right time, so they are able to drive towards better, more efficient care delivery.”

 

SourceRubiconMD
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy